Management of oromandibular dystonia with botulinum A toxin: a series of cases

详细信息    查看全文

• 作者：T.A. Teemul ^{trevor.teemul@nhs.net} ; R. Patel ^{radhe.patel359@gmail.com} ; A. Kanatas ; ^{a.kanatas@doctors.org.uk} ; L.M. Carter ^{lachlan.carter@nhs.net}
• 关键词：Oromandibular Dystonia ; Botulinum A toxin ; Meige syndrome
• 刊名：British Journal of Oral and Maxillofacial Surgery
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：54
• 期：10
• 页码：1080-1084
• 全文大小：692 K
• 卷排序：54

文摘

Oromandibular dystonia is a disorder of movement that is often misdiagnosed. We present our experience of six patients treated with botulinum A toxin, for whom we recorded the symptoms, the group of muscles targeted, and the quantity of botulinum toxin used. We used the Glasgow Benefit Inventory (GBI) questionnaire to record and analyse outcomes after treatment. Five of the six patients had a good outcome as recorded by the GBI, the mean (SD) score of which was +40 (28), which reflected that the patients were well satisfied. The overall improvement in the categories of general health, social health, and physical health were 82%, 37%, and 31%, respectively. Botulinum type A toxin is an effective treatment of oromandibular dystonia. It is important for clinicians to recognise the condition, as treatment is well-tolerated and can improve quality of life.